Author:
Narra Ravi Kishore,Flynn Kathryn E.,Atallah Ehab
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference51 articles.
1. Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30(11):2317–28. doi: 10.1185/03007995.2014.944973 .
2. Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma. 2011;52(6):1017–23. doi: 10.3109/10428194.2011.560310 .
3. Experts in Chronic Myeloid L. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–4442. doi: 10.1182/blood-2013-03-490003 .
4. Hagop KM. The arrival of generic imatinib into the U.S. market: an educational event. THE ASCO POST; 2016.
5. Cancer Stat Facts: Chronic Myeloid Leukemia (CML);SEER database; National Cancer Institute. Bethesda, MD. Accessed 11 June 2017; https://seer.cancer.gov/statfacts/html/cmyl.html .
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献